Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
PA Ascierto, PF Ferrucci, R Fisher, M Del Vecchio… - Nature medicine, 2019 - nature.com
Abstract Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor
responses that are induced by the combined inhibition of BRAF and MEK. Here we …
responses that are induced by the combined inhibition of BRAF and MEK. Here we …
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
PA Ascierto, PF Ferrucci, R Fisher, M Del Vecchio… - Nature Medicine, 2019 - pure.au.dk
Abstract Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor
responses that are induced by the combined inhibition of BRAF and MEK 1. Here we …
responses that are induced by the combined inhibition of BRAF and MEK 1. Here we …
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
PA Ascierto, PF Ferrucci, R Fisher… - Nature …, 2019 - pubmed.ncbi.nlm.nih.gov
Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor responses
that are induced by the combined inhibition of BRAF and MEK 1. Here we performed a …
that are induced by the combined inhibition of BRAF and MEK 1. Here we performed a …
[引用][C] Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
PA Ascierto, PF Ferrucci, R Fisher, M Del Vecchio… - Nature Medicine, 2019 - cir.nii.ac.jp
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
PA Ascierto, PF Ferrucci, R Fisher… - Nature …, 2019 - research.regionh.dk
Abstract Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor
responses that are induced by the combined inhibition of BRAF and MEK1. Here we …
responses that are induced by the combined inhibition of BRAF and MEK1. Here we …
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
PA Ascierto, PF Ferrucci, R Fisher, M Del Vecchio… - paper.sciencenet.cn
Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor responses
that are induced by the combined inhibition of BRAF and MEK1. Here we performed a …
that are induced by the combined inhibition of BRAF and MEK1. Here we performed a …
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
PA Ascierto, PF Ferrucci, R Fisher, M Del Vecchio… - Nature …, 2019 - europepmc.org
Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor responses
that are induced by the combined inhibition of BRAF and MEK 1. Here we performed a …
that are induced by the combined inhibition of BRAF and MEK 1. Here we performed a …
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
PA Ascierto, PF Ferrucci, R Fisher… - NATURE …, 2019 - usiena-air.unisi.it
Abstract Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor
responses that are induced by the combined inhibition of BRAF and MEK1. Here we …
responses that are induced by the combined inhibition of BRAF and MEK1. Here we …
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
PA Ascierto, PF Ferrucci, R Fisher, M Del Vecchio… - Nature Medicine, 2019 - go.gale.com
Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor responses
that are induced by the combined inhibition of BRAF and MEK. sup. 1. Here we performed a …
that are induced by the combined inhibition of BRAF and MEK. sup. 1. Here we performed a …
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
PA Ascierto, PF Ferrucci, R Fisher, M Del Vecchio… - paper.sciencenet.cn
Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor responses
that are induced by the combined inhibition of BRAF and MEK1. Here we performed a …
that are induced by the combined inhibition of BRAF and MEK1. Here we performed a …